This article summarized the latest R&D progress of Deoxycholic acid, the Mechanism of Action for Deoxycholic acid, and the drug target R&D trends for Deoxycholic acid.

Elpiscience Biopharmaceuticals has revealed that the initial patient has received a dose in a Phase 1 clinical study of the anti-LILRB2 monoclonal antibody ES009 in Australia.

Me-better class of innovative drugs refers to new drugs that have clinical efficacy or safety superior to that of the original innovative drug.

This article summarized the latest R&D progress of Decitabine, the Mechanism of Action for Decitabine, and the drug target R&D trends for Decitabine.

FIC stands for First in Class, which refers to pioneering drugs.

Edgewise Therapeutics, Inc., has initiated the participation induction for GRAND CANYON, an international principal examination of EDG-5506 designed for Becker patients.

This article summarized the latest R&D progress of Crisaborole, the Mechanism of Action for Crisaborole, and the drug target R&D trends for Crisaborole.

Arcturus Therapeutics and the Cystic Fibrosis Foundation continue partnership to further the development of ARCT-032, an experimental mRNA therapy for Cystic Fibrosis.

ROCK, also known as Rho-associated coiled-coil kinases, is a class of serine/threonine protein kinases that play an important role in various common cellular functions such as cell proliferation, cell apoptosis, and gene expression.

This article summarized the latest R&D progress of Clofazimine, the Mechanism of Action for Clofazimine, and the drug target R&D trends for Clofazimine.

Inozyme Pharma reports encouraging preliminary results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies.

This article summarized the latest R&D progress of Clevidipine, the Mechanism of Action for Clevidipine, and the drug target R&D trends for Clevidipine.